Last data update: May 13, 2024. (Total: 46773 publications since 2009)
Records 1-2 (of 2 Records) |
Query Trace: Angra PK[original query] |
---|
Sputum smear microscopy in the Xpert ® MTB/RIF era.
Van Deun A , Tahseen S , Affolabi D , Hossain MA , Joloba ML , Angra PK , Ridderhof JC , de Jong BC , Rieder HL . Int J Tuberc Lung Dis 2018 23 (1) 12-18 A balanced perspective is advocated for the assessment and application of the most recent and the oldest diagnostic methods for pulmonary tuberculosis (TB)—the molecular Xpert(®) MTB/RIF assay and microscopy for acid-fast bacilli. We discuss their respective merits and shortcomings and identify threats that may hamper their use in TB control. Neither test on its own provides all the information needed for diagnosis and treatment monitoring. Considering all aspects important for both individual patient care and disease control, neither seems ‘better' than the other. The required advancement of microscopy had already been hampered before the introduction of the GeneXpert technology by unsuccessful and probably misguided attempts to decentralise culture-based diagnosis and drug susceptibility testing. It seems evident that systematic replacement of microscopy by Xpert is not a viable option for the foreseeable future. Instead, the two methods should complement each other to arrive at a comprehensive, accessible and continuous service for a maximum number of patients. This will intrinsically prioritise targeting the most potent transmitters with the worst prognosis, simultaneously offering optimised prospects for efficient TB control. New microscopy and Xpert applications are expected to ultimately make control programmes independent of culture-based methods in diagnosis, treatment monitoring and outcome assessment. |
Performance of tuberculosis drug susceptibility testing in the United States laboratories from 1994-2008
Angra PK , Taylor TH , Iademarco MF , Metchock B , Astles JR , Ridderhof JC . J Clin Microbiol 2012 50 (4) 1233-9 We present a statistical summary of results from the Model Performance Evaluation Program (MPEP) for Mycobacterium tuberculosis Drug Susceptibility Testing, 1994-2008 implemented by the U.S. Centers for Disease Control and Prevention (CDC). During that period, a total of 57,733 test results for culture isolates were reported by 216 participating laboratories for the first-line anti-tuberculosis drugs used in the United States- isoniazid (INH), rifampin (RMP), ethambutol (EMB), and pyrazinamide (PZA). Using Clinical Laboratory and Standards Institute (CLSI) recommended concentrations for one or more of three methods, agar proportion (AP), BACTEC460 (BACTEC), and MGIT-960 (MGIT), yielded overall agreement of 97.0% for first-line drugs. For susceptible strains, agreement was 98.4%; for resistant strains, agreement was 91.0%, with significantly lower accuracy (Chi-sq p<0.0001). For resistant strains, overall agreement by methods was: AP 91.3%; BACTEC 93.0%; and MGIT 82.6% and by drugs was: INH 92.2%; RMP 91.5%; EMB 79.0%; and PZA 97.5%. For some strains, performance by method varied significantly. Use of duplicate strains in the same shipment and repeat strains over time, revealed consistent performance even for strains with higher levels of inter-laboratory discordance. No overall differences in performance between laboratories were observed based on volume of testing or type of facility (e.g., health department, hospital, independent). By all methods, decreased performance was observed for strains with low-level INH resistance, RMP resistance, and EMB-resistant strains. These results demonstrate a high level of performance in detection of drug resistant M. tuberculosis in U.S. laboratories. |
- Page last reviewed:Feb 1, 2024
- Page last updated:May 13, 2024
- Content source:
- Powered by CDC PHGKB Infrastructure